Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Amlodipine 2.5 mg + Telmisartan 20 mg: Amlodipine 2.5 mg + Telmisartan 20 mg Once Daily
Control Intervention1: Amlodipine 5 mg: Amlodipine 5 mg once daily
Sponsors
Dr Kuldeep Desai
Eligibility
Inclusion criteria
Inclusion criteria: 1. Informed consent from the participant as documented by signature. 2. Age 18 to 65 years. 3. Newly diagnosed, untreated hypertension according to JNC 8 guidelines: (a) Age 18 to 59 years: SBP more than equal to 140 mmHg or DBP more than equal to 90 mmHg (b) Age 60 to 65 years: SBP more than equal to 150 mmHg or DBP more than equal to 90 mmHg 4. History of smoking and alcohol consumption.
Exclusion criteria
Exclusion criteria: 1. Patients with secondary hypertension. 2. Pregnant or lactating women. 3. Severe hepatic impairment. 4. Renal impairment. 5. Hypersensitivity to amlodipine, telmisartan, or any component of the formulations. 6. Participation in another interventional clinical trial within 4 weeks prior to baseline and during the current trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Possible Outcome-Amlodipine 2.5 mg + Telmisartan 20 mg more effective in reducing blood pressure compared to Amlodipine 5 mg.Timepoint: 3 Months | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the incidence and severity of adverse drug reactions, compare changes in Body Mass Index (BMI) and evaluate changes in lipid profile parameters between the two groups.Timepoint: 3 Months | — |
Countries
India
Contacts
Public ContactDr Suraj Tripathi
Zydus Medical College and Hospital
Outcome results
None listed